Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Blue Apron’s IPO has no pop but plenty of questions

The meal-kit company raised $300 million in its public offering.

Meal Delivery Service Blue Apron To Go Public On NYSE
Meal Delivery Service Blue Apron To Go Public On NYSE
Scott Eisen / Getty
Jason Del Rey
Jason Del Rey has been a business journalist for 15 years and has covered Amazon, Walmart, and the e-commerce industry for the last decade. He was a senior correspondent at Vox.

Blue Apron started trading on the New York Stock Exchange today, opening at about $10 a share after cutting its IPO price to the same number amid questions about whether it can grow profitably as well as the potential of future competition from an Amazon-owned Whole Foods.

The five-year-old meal-kit company, based in New York City, raised $300 million in the offering that gave it a market cap around the same $2 billion number it was valued at in a private fundraising round several years ago. The stock was trading at around $10.65 at noon eastern on Thursday.

Blue Apron’s revenue grew 10x between 2014 and 2016 to nearly $800 million last year, proving that Americans had strong interest in trying out a new way to grocery shop and cook. Blue Apron ships subscribers recipes and pre-portioned ingredients to make three home-cooked meals a week.

But rising marketing costs and steep losses have some investors questioning the long-term feasibility of the Blue Apron model. There’s also a concern that Amazon and Whole Foods could get more aggressive in the market following approval of the $14 billion acquisition.

In an interview with CNBC on Thursday, co-founder and CEO Matt Salzberg dismissed concerns over the current stock price as well as customer churn.

Instead, he said his company is working hard on developing new products to make more money from existing customers as well as new offerings that might attract customers who haven’t found Blue Apron to be a fit just yet. That may include ingredients for meals other than dinner, as well as a different “cadence” of deliveries, in his words.

Salzberg is one of many top industry entrepreneurs and CEOs who will appear onstage at Code Commerce on September 13 and 14 in New York City. By then, we’ll have a lot more to discuss.


This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh